Fig. 2From: Selinexor plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm studyDuration of response/treatment by individual responders. An arrow at the end indicates the treatment was ongoing as of data cut-offBack to article page